Published in Arthritis Res Ther on January 01, 2007
The innate immune system in SLE: type I interferons and dendritic cells. Lupus (2008) 2.52
Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med (2008) 1.82
Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol (2015) 1.66
Estrogen receptor alpha modulates Toll-like receptor signaling in murine lupus. Clin Immunol (2012) 1.53
Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol (2009) 1.12
Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm (2010) 0.98
Microparticles as a source of extracellular DNA. Immunol Res (2011) 0.95
Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther (2009) 0.93
Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? Clin Dev Immunol (2011) 0.87
The role of innate immunity in donor organ procurement. Semin Immunopathol (2011) 0.83
Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus. Rheumatol Int (2012) 0.81
EBI2 is a negative regulator of type I interferons in plasmacytoid and myeloid dendritic cells. PLoS One (2013) 0.79
Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation. Clin Exp Med (2011) 0.79
The macrophages in rheumatic diseases. J Inflamm Res (2016) 0.78
Changes in the expression of the Toll-like receptor system in the aging rat kidneys. PLoS One (2014) 0.76
The danger of sex and death in Scarf1(-/-) autoimmune mice. Nat Immunol (2013) 0.75
Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention. Curr Allergy Asthma Rep (2012) 0.75
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol (2005) 8.33
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Viruses and interferon: a fight for supremacy. Nat Rev Immunol (2002) 7.92
Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science (2004) 6.07
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 5.30
Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity (2005) 5.23
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 4.42
A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med (2001) 4.35
Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol (2002) 4.12
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 3.93
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A (2006) 3.70
Clearance of apoptotic cells: getting rid of the corpses. Mol Cell (2004) 3.64
Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A (2007) 3.41
Activation of autoreactive B cells by CpG dsDNA. Immunity (2003) 3.40
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med (2004) 3.34
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med (2001) 3.03
Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med (1998) 3.01
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med (2005) 2.89
Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med (1998) 2.69
Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest (2006) 2.63
Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol (2003) 2.45
Structural insights into RNA quality control: the Ro autoantigen binds misfolded RNAs via its central cavity. Cell (2005) 2.40
Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity (2006) 2.36
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol (2005) 2.31
Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol (2006) 2.27
Microarray analysis of interferon-regulated genes in SLE. Autoimmunity (2003) 2.24
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol (1988) 2.19
Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med (1995) 2.09
CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol (2004) 2.08
Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest (1997) 2.04
The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev (1999) 1.88
Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum (2006) 1.87
Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 1.84
Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol (2006) 1.80
Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med (2004) 1.79
Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol (1999) 1.78
The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol (2000) 1.78
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood (2005) 1.74
Type I IFN protects against murine lupus. J Immunol (2004) 1.71
The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol (2003) 1.67
Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol (1995) 1.62
Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. J Immunol (1989) 1.50
Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci U S A (1993) 1.40
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest (1999) 1.24
T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol (2006) 1.23
Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int Immunol (2006) 1.21
Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum (2001) 1.18
Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum (2006) 1.15
The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol (2005) 1.11
Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am (2004) 1.09
Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol J (2006) 1.08
Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther (2006) 1.06
A SmD peptide induces better antibody responses to other proteins within the small nuclear ribonucleoprotein complex than to SmD protein via intermolecular epitope spreading. J Immunol (2007) 0.91
Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin Immunol (2005) 0.91
Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest (2006) 0.88
Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J Immunol (2006) 0.84
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
Activation of autoreactive B cells by CpG dsDNA. Immunity (2003) 3.40
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med (2004) 3.34
Response to self antigen imprints regulatory memory in tissues. Nature (2011) 2.96
Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev (2005) 2.47
Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol (2007) 2.12
Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol (2012) 1.71
Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol (2011) 1.67
The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells. J Leukoc Biol (2013) 1.52
Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol (2009) 1.42
Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol (2008) 1.39
Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity (2010) 1.35
IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol (2009) 1.33
Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J Immunol (2009) 1.30
Poly(I:C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol (2010) 1.17
Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum (2006) 1.15
Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol (2007) 1.11
Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 1.10
DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. Arthritis Res Ther (2009) 1.07
Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J Immunol (2004) 1.06
Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol (2002) 0.99
Visualizing the onset and evolution of an autoantibody response in systemic autoimmunity. J Immunol (2005) 0.98
Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem (2012) 0.98
Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides. J Immunol (2009) 0.98
Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death. PLoS One (2011) 0.96
Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum (2012) 0.93
Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. Int Immunol (2013) 0.92
Cutting edge: Self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J Immunol (2014) 0.92
A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation. J Biol Chem (2002) 0.91
Toll-like receptors and activation of autoreactive B cells. Curr Dir Autoimmun (2003) 0.90
G alpha q-containing G proteins regulate B cell selection and survival and are required to prevent B cell-dependent autoimmunity. J Exp Med (2010) 0.89
FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responses. Eur J Immunol (2010) 0.88
RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity (2010) 0.87
DNA and RNA autoantigens as autoadjuvants. J Endotoxin Res (2006) 0.87
Early consequences of 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on the activation and survival of antigen-specific T cells. Toxicol Sci (2004) 0.86
T-bet: the Toll-bridge to class-switch recombination? Nat Immunol (2003) 0.86
Fas-ligand--iron fist or Achilles' heel? Clin Immunol (2002) 0.86
Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus. J Immunol (2013) 0.85
Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand. Cancer Res (2007) 0.83
A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Invest Ophthalmol Vis Sci (2005) 0.81
Selective binding of anti-DNA antibodies to native dsDNA fragments of differing sequence. Immunol Lett (2012) 0.78
Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells. Int Immunol (2004) 0.77
Toll-like receptor-dependent immune complex activation of B cells and dendritic cells. Methods Mol Biol (2009) 0.77
Intricate connections between innate and adaptive autoimmunity. Curr Opin Immunol (2007) 0.77
B cells and dendritic cells from V kappa 8 light chain transgenic mice activate MRL-lpr/gld CD4+ T cells. J Immunol (2006) 0.76
Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res (2011) 0.76
A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest (2017) 0.75
The 2010 Midwinter Conference of Immunologists at Asilomar. Nat Immunol (2010) 0.75
Organ-specific and systemic autoimmune diseases. Curr Opin Immunol (2013) 0.75